Milk-derived nanoparticles may enable physicians to target aggressive bile duct cancer
Why it matters: Targeted nano‑therapy could transform treatment for aggressive bile‑duct cancer, offering hope where options are scarce.
- Mayo Clinic researchers develop milk‑derived nanoparticles as guided delivery vehicles for cholangiocarcinoma (per JHEP Reports).
- Milk‑derived nanoparticles can be loaded with chemotherapy and selectively accumulate in bile duct tumors, reducing off‑target effects (per study).
- Pre‑clinical mouse trials demonstrate significant tumor reduction and improved survival, but human trials are still needed (adds nuance).
Mayo Clinic scientists have engineered milk‑derived nanoparticles that home in on cholangiocarcinoma cells, delivering chemotherapy directly to tumors while sparing healthy tissue. Published in JHEP Reports, the pre‑clinical work shows tumor shrinkage in mouse models and paves the way for a targeted, less toxic therapy for a cancer that currently has few options.
